NeoGenomics expands partnership with Indica Labs after stock ends session up 1.2%

NeoGenomics expands partnership with Indica Labs after stock ends session up 1.2%
NeoGenomics stock rises 1.2% today

NeoGenomics has expanded its partnership with Indica Labs to further develop its AI-powered digital pathology. Shares are up 1.2% on the day at $16.88.

Highlights

  • NeoGenomics has expanded its partnership with Indica Labs to accelerate development of AI-enabled digital pathology solutions.
  • 32 of 48 analysts rate NeoGenomics stock a buy, and the median price target is $19, about 12.5% above current levels.
  • Shares of NeoGenomics are up 1.2% on the day at $16.88.

NeoGenomics has expanded its partnership with Indica Labs, a global leader in AI-powered digital pathology. The collaboration is intended to scale the NeoGenomics digital pathology program, according to FinancialContent. This collaboration is expected to provide more timely and consistent diagnostic insights, BioPharmaWatch reported.

Bullish structure holds as price tests weekly high resistance

The intraday range in the latest session stretched from $16.45 to the weekly high at $17.25, well above the average for the week. Shares of NeoGenomics are trading in a split daily structure, with price currently below the MA-20 and MA-50 but holding above the MA-200. This setup aligns with a broader bullish chart structure, though immediate resistance remains at the weekly high.

Odds tilt to the downside as traders eye the $17.25 close

A close above $17.25 would indicate that buyers are prepared to continue the advance. Price fluctuated sharply within the session, moving between $16.45 and $17.25. Even with a sustained move higher and a firm trend over the past week, the outlook for the coming trading week shows a 42% probability of upside and a 58% probability of downside, with trading likely between $16.07 and $17.68. A drop below $15.44 would show the move is being faded. On the weekly chart, the longer-term picture stays constructive.

Previously it was reported that NeoGenomics maintained a broadly bullish technical structure following the launch of its PTEN IHC CDx test. The latest partnership expansion with Indica Labs adds a new dimension to NeoGenomics’ technology platform, and traders should monitor whether price action around the $17.25 resistance leads to a shift in the prevailing trading range.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.